Selinexor

Active substance selinexor
Holder Karyopharm
Status Running
Indication Adult patients with relapsed or refractory multiple myeloma (RRMM), who have have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
Public documents Approbation
  Information for the patient
  Informed consent
Last update 10/08/2022

 

Last updated on 28/09/2022